« Back to Record
Citation APA

Di Leo, A., Tanner, M., Desmedt, C., Paesmans, M., Cardoso, F., Durbecq, V., Chan, S., Perren, T. J., Aapro, M., Sotiriou, C., Piccart-Gebhart, M., Larsimont, D., Isola, J., & TAX 303 translational study team, (2007). p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annals of oncology, 18(6), 997-1003. doi:10.1093/annonc/mdm075


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/54561

Di Leo, A., Tanner, M., Desmedt, C., Paesmans, M., Cardoso, F., Durbecq, V., Chan, S., Perren, T. J., Aapro, M., Sotiriou, C., Piccart-Gebhart, M., Larsimont, D., Isola, J., & TAX 303 translational study team, (2007). p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annals of oncology, 18(6), 997-1003. doi:10.1093/annonc/mdm075